Atom Therapeutics key facts
as of Oct 2026- Developer and researcher of new drugs and treatments designed to treat metabolic diseases and cancers.
- Atom Therapeutics is valued at approximately $425.1M as of Oct 2026 (last reported valuation).
- It has raised $70.0M; the latest was IPO in Sep 2025.
- Notable investors include Suzhou Oriza Holdings Corporation, HSG (Hong Kong), Fortune Capital, Shenzhen Yifeng Investment Management Enterprise, Heda Ventures — 15 tracked in total.
- Status: In IPO Registration.
Atom Therapeutics's last reported valuation, Aug 2025. Nothing priced has surfaced since.
- ·The complete investor list: 15 names
- ·Watch Atom Therapeutics: the Monday email on marks, rounds and moves
Atom Therapeutics funding rounds
No funding rounds for Atom Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Atom Therapeutics
15+Membership and data by Private Market View
Atom Therapeutics valuation
Atom Therapeutics's last reported valuation was $425 million in Aug 2025. No priced round, secondary trade or fund mark has surfaced since.
Atom Therapeutics investors
15 investors are on record for Atom Therapeutics, including Suzhou Oriza Holdings Corporation, HSG (Hong Kong), Fortune Capital and Shenzhen Yifeng Investment Management Enterprise.
About Atom Therapeutics
Developer and researcher of new drugs and treatments designed to treat metabolic diseases and cancers. The company's treatments focus on the field of metabolism and inflammation, which includes Non-Alcoholic SteatoHepatitis (NASH), gout, diabetes and colon cancers, providing patients with more effective medication and treatments for cancer and metabolic diseases.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2012
- Employees
- 60
- Website
- atomthera.us/
- Ownership
- In IPO Registration
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.